Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Rating of “Buy” from Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have earned an average recommendation of “Buy” from the eight brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $206.67.

KRYS has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th. Citigroup lifted their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Stifel Nicolaus increased their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $212.00 target price on shares of Krystal Biotech in a report on Wednesday, December 18th.

Krystal Biotech Trading Up 1.2 %

Shares of KRYS opened at $158.33 on Wednesday. The company has a market cap of $4.55 billion, a price-to-earnings ratio of 89.45 and a beta of 0.85. The company’s fifty day simple moving average is $176.51 and its 200 day simple moving average is $184.05. Krystal Biotech has a 1-year low of $107.50 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. During the same period in the prior year, the firm earned ($0.67) EPS. Krystal Biotech’s quarterly revenue was up 879.9% compared to the same quarter last year. As a group, research analysts forecast that Krystal Biotech will post 2.97 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. 14.10% of the stock is owned by insiders.

Institutional Trading of Krystal Biotech

A number of institutional investors have recently modified their holdings of the stock. State Street Corp increased its position in shares of Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after purchasing an additional 119,936 shares during the period. Geode Capital Management LLC raised its position in shares of Krystal Biotech by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after buying an additional 11,411 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Krystal Biotech by 1.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock valued at $106,593,000 after buying an additional 7,537 shares in the last quarter. Hood River Capital Management LLC lifted its holdings in shares of Krystal Biotech by 5.1% during the 2nd quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock worth $95,694,000 after acquiring an additional 25,507 shares during the period. Finally, Franklin Resources Inc. boosted its position in shares of Krystal Biotech by 34.2% during the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after acquiring an additional 62,178 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).